Physician profile
Amanda Guentner
NPI 1346533213
$4,311.98
in general payments reported to CMS, 2019-2025
25 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $13.33 · 2021: $182 · 2022: $762 · 2023: $993 · 2024: $1,195 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $897.01 | 2021-2025 | |
| Janssen Biotech, INC. | $848.94 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $444.75 | 2022-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $288.03 | 2022-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $282.37 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.68 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Daiichi Sankyo INC. | $180.44 | 2021-2025 | Injectafer |
| Braintree Laboratories, INC. | $159.26 | 2019-2020 | |
| Celgene Corporation | $117.78 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $112.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $83.89 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $79.80 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $76.75 | 2022-2023 | |
| Amgen INC. | $74.60 | 2022-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $65.85 | 2024 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $57.71 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $54.59 | 2025 | Vegzelma |
| Pfizer INC. | $47.53 | 2023-2025 | |
| Vivus LLC | $32.38 | 2022 | |
| Genzyme Corporation | $30.51 | 2024 | |
| Qol Medical, LLC | $28.94 | 2024 | Sucraid |
| Redhill Biopharma INC. | $28.03 | 2021 | |
| Novo Nordisk INC | $24.47 | 2025 | Wegovy |
| Gilead Sciences, INC. | $22.01 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Guentner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.